Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors

Annals of Pharmacotherapy

Volumn 43, Issue 10, 2009, Pages 1658-1666

  Eng, Hooi Tan ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Cetuximab; Cutaneous effects; Epidermal growth factor receptor inhibitor; Erlotinib; Gefitinib; Panitumumab; Skin toxicity

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; BORIC ACID; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; FUSIDIC ACID; GEFITINIB; ISOTRETINOIN; KETOCONAZOLE; LYMECYCLINE; METRONIDAZOLE; MINOCYCLINE; PANITUMUMAB; PENICILLIN G; PHYTOMENADIONE; PIMECROLIMUS; POVIDONE IODINE; PSEUDOMONIC ACID; RETINOID; STEROID; TAZAROTENE; TETRACYCLINE; TRIAMCINOLONE ACETONIDE; TRICLOSAN; ZINC OXIDE;

DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACE ERYTHEMA; FOLLOW UP; HEADACHE; HUMAN; MANAGEMENT; MEDICAL LITERATURE; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN DISEASE; SKIN IRRITATION; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSIS;

ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ERUPTIONS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 70449462258     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M241     Document Type: Review

References (36)

1. Product information. Iressa (gefitinib). Cheshire, UK: AstraZeneca, June 2005. www.astrazeneca-us.com/pi/iressa.pdf (accessed 2009 Mar 5).
2. Product information. Tarceva (erlotinib). Seymour, IN: Schwarz Pharma Manufacturing, Genentech, September 2008. www.gene.com/gene/ products/information/pdf/tarceva-prescribing.pdf (accessed 2009 Mar 5).
3. Product information. Erbitux (cetuximab). Branchburg, NJ: ImClone, November 2008. http://packageinserts.bms.com/pi/pi-erbitux.pdf (accessed 2009 Mar 5).
4. Product information. Vectibix (panitumumab). Thousand Oaks, CA: Amgen, February 2009. http://packageinserts.bms.com/pi/pi-erbitux.pdf (accessed 2009 May 22).
5. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-621 DOI 10.1634/theoncologist.12-5-610 (Pubitemid 350012125)
6. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812 DOI 10.1038/nrc1970
7. Chou LS, Garey J, Oishi K, Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer 2006;8: S15-22. Epub 16 Jun 2008. DOI 10.3816/CLC.2006.s.009
8. Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008;66:155-162 Epub 20 Dec 2007. DOI 10.1016/j.critrevonc.2007.10.004
9. National Cancer Institute. Common terminology criteria for adverse events (Version 3.0). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf (accessed 2009 Jan 20).
10. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992;268: 2420-2425 Epub 4 Nov 1992. DOI 10.1001/jama.268.17.2420
11. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-72
12. Adams DH, Terri N. A case report and discussion of cetuximab-induced folliculitis. Am J Clin Dermatol 2006;7:333-336 DOI 10.2165/00128071-200607050- 00008 (Pubitemid 46998584)
13. Racca P, Fanchini L, Caliendo V, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7: 48-54. Epub 15 May 2008. DOI 10.3816/CCC.2008.n.007 (Pubitemid 351252451)
14. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238-241 Epub 29 Jun 2004. DOI 10.1111/j.1365-2133.2004.06026. x
15. Micantonio T, Fargnoli MC, Ricevuto E, Ficorella C, Marchetti P, Peris K. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005;141:1173-1174 DOI 10.1001/archderm.141.9.1173
16. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-130 DOI 10.1001/archderm.138.1.129
17. Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème. Radiol Oncol 2008;42:215-224 Epub 29 Dec 2008. DOI 10.2478/v10019-008-0022-4
18. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849-851 Epub 18 Aug 2005. DOI 10.1111/j.1365-2133.2005. 06835.x (Pubitemid 41415923)
19. Lacouture ME, Basti S, Patel J, Benson A. The SERIES Clinic: an interdisciplinary approach to the management of toxicities to EGFR inhibitors. J Support Oncol 2006;4:236-238 (Pubitemid 43756991)
20. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007;56:500-505 Epub 12 Dec 2006. DOI 10.1016/j.jaad.2006.06.046
21. Robert C, Soria JC, Chosidow O. Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib. Targeted Oncol 2006;1:100-103 Epub 7 Apr 2006. DOI 10.1007/s11523-006-0013-6
22. Vezzoli P, Marzano AV, Onida F, et al. Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol 2008;88: 84-86 DOI 10.2340/00015555-0330
23. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 2006;22:152-162 Epub 5 Aug 2006. DOI 10.1016/j.soncn.2006.04. 005
24. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo- controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-853 Epub 15 Aug 2008. DOI 10.1002/cncr.23621
25. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-5396 Epub 1 Dec 2007. DOI 10.1200/JCO.2007.12.6987 (Pubitemid 350232214)
26. Monti M, Mancini LL, Ferrari B, Rahal D, Santoro A. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 2003;21:4651-4653 Epub 15 Dec 2003. DOI 10.1200/JCO.2003.04.169
27. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433 Epub 12 Jul 2005. DOI 10.1093/annonc/mdi279 (Pubitemid 41222414)
28. Segaert S. Management of skin toxicity of epidermal growth factor receptor inhibitors. Targeted Oncol 2008;3:245-251 Epub 8 Oct 2008. DOI 10.1007/s11523-008-0092-7
29. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003;4:366-369 Epub 10 Apr 2008. DOI 10.3816/CLC.2003.n.016 (Pubitemid 36798559)
30. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43:845-851 Epub 7 Feb 2007. DOI 10.1016/j.ejca.2006.11.016
31. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin (abstract 3036). J Clin Oncol 2006;24:18S.
32. Perez-Soler R, Zou Y, Li T, Ling Y. Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of the skin rash (abstract 9124). J Clin Oncol 2007;25:18S.
33. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606. Epub 15 Jul 2005. DOI 10.1111/j.1610-0387.2005.05058.x (Pubitemid 41647826)
34. Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology 2007;21:17-21. Epub 2 October 2007.
35. Segaert S, Van Cutsem E. Clinical management of EGFRI dermatologic toxicities: the European perspective. Oncology 2007;21:22-26 Epub 2 October 2007.
36. Yamazaki N, Muro K. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective. Oncology 2007;21:27-28 Epub 2 October 2007.